Viewing posts categorised under: Biotech

The PD-1 Era Is Officially Here

On July 4th Ono Pharmaceuticals announced that it had received manufacturing and marketing approval in Japan for nivolumab (Opdivo®), a PD-1 monoclonal antibody, for the treatment of unresectable melanoma. PD-1 and PD-L1 inhibitors work to block the immune-suppressive effects of PD-1 (releasing the brakes, so to speak) thereby allowing the immune system to attack and […]

Dr. Dan Von Hoff honored at Governor’s Celebration

Our colleague Dan Von Hoff, M.D., a founder and shareholder of Medelis and the chairman of our medical advisory board, was recently named Arizona’s ‘Community Service Leader of the Year’ at the 2008 Governor’s Celebration of Innovation in Phoenix. Dr. Von Hoff is a world-renowned cancer researcher and member of the National Institute of Health’s National Cancer Advisory Board, has devoted more than 35 years to two primary goals: identifying the best new anti-cancer agents to treat patients and curing pancreatic cancer. He has published more than 540 scientific papers, more than 130 book chapters, and nearly 950 scientific abstracts. He holds a dozen patents for new anti-cancer agents and medical devices.

Medelis expands CRO services into Europe, appoints Dr. Deirdre Tessman to run the operation

Medelis is very pleased to announce that our colleague Deirdre Tessman, Ph.D., has officially joined our organization to lead our new Medelis Europe division as its Managing Director. She brings 10 years of European CRO experience and 30+ years in worldwide drug development and regulatory experience.

Meet us at BioPartnering Europe

We’re gearing up to attend the BioPartnering Europe conference in London, UK (Oct. 12-14, 2008) to talk about our new Medelis Europe division and the CRO services we’re offering to European, U.S. and Asian sponsors looking to bring drugs to the U.S. and European markets. If you’re attending the conference, we invite you to join us for our open house on Monday, October 13.